3/11
09:06 pm
hcm
HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ... [Yahoo! Finance]
Medium
Report
HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ... [Yahoo! Finance]
3/10
03:37 pm
hcm
HUTCHMED (HCM) had its price target lowered by Bank of America Corporation from $21.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
HUTCHMED (HCM) had its price target lowered by Bank of America Corporation from $21.00 to $20.00. They now have a "buy" rating on the stock.
3/9
05:30 am
hcm
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
Low
Report
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
3/6
03:30 am
hcm
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
Low
Report
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
3/5
09:32 pm
hcm
HUTCHMED H2 Earnings Call Highlights [Yahoo! Finance]
Low
Report
HUTCHMED H2 Earnings Call Highlights [Yahoo! Finance]
3/5
06:00 am
hcm
HUTCHMED Reports 2025 Full Year Results and Business Updates
Low
Report
HUTCHMED Reports 2025 Full Year Results and Business Updates
3/4
03:30 am
hcm
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
Low
Report
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
2/6
03:30 am
hcm
HUTCHMED to Announce 2025 Final Results
Medium
Report
HUTCHMED to Announce 2025 Final Results
1/20
06:59 am
hcm
HUTCHMED (NASDAQ:HCM) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Low
Report
HUTCHMED (NASDAQ:HCM) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
1/13
11:00 pm
hcm
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
Low
Report
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
1/6
07:00 pm
hcm
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Medium
Report
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
1/4
07:00 pm
hcm
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
Low
Report
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
12/30
05:00 am
hcm
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
Low
Report
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
12/29
05:20 am
hcm
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma [Yahoo! Finance]
Low
Report
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma [Yahoo! Finance]
12/29
03:35 am
hcm
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
Low
Report
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma